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Introduction: Colchicine has the potential in reducing patient morbidity and mortality 
in	COVID-	19	infection	owing	to	its	anti-	inflammatory	properties.	This	study	aims	to	
determine the efficacy of colchicine in optimizing inflammatory hematological bio-
marker	levels	among	COVID-	19	patients.
Methods: In	 accordance	 to	Preferred	Reporting	 Items	 for	 Systematic	 Reviews	 and	
Meta-	Analyses	 (PRISMA)	 2020	 statement	 guidelines,	 a	 systematic	 search	 was	
conducted	 using	 the	 following	 keywords:	 Colchicine,	 covid*,	 SARS-	CoV-	2,	 anti-	
inflammatory,	 trials,	 clinical,	 hematological,	 laboratory.	 Databases	 were	 searched	
from	December	2019	until	August	 26,	 2021:	MEDLINE/PubMed,	Web	of	 Science,	
Cochrane,	Scopus,	and	EMBASE.	Other	sources	were	located	through	ClinicalTrials.
Gov,	 manually	 searching	 SAGE,	 Science	 Direct,	 Elsevier,	 and	 Google	 Scholar.	 The	
meta-	analysis	was	conducted	using	Review	Manager	5.4.
Results: In	total,	six	studies	were	included,	of	which	four	reported	c-	reactive	protein	
(CRP)	 standardized	mean	 reductions	 in	 the	 colchicine	group	 (N	=	 165)	 as	opposed	
to	 the	 control	 (N	= 252; SMD =	 −0.49,	p <	 0.001).	On	 noting	 lactate	 dehydroge-
nase	 (LDH)	 values	 post	 treatment,	 the	 colchicine	 group	 (N	=	 204)	 showed	 signifi-
cant	reductions	at	the	end	of	treatment	compared	to	control	(N	=	290;	SMD	=	−0.85,	




the clinical and laboratory parameters of patients in further trials to consider colchi-
cine	as	a	strong	candidate	for	an	adjunct	to	COVID-	19	treatment.
K E Y W O R D S
colchicine,	COVID-	19,	CRP,	D-	dimer,	LDH
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1  |  INTRODUC TION
There is evidence of the underlying inflammatory processes 
contributing	 to	 COVID-	19	 infection	 severity.1 The association 
between	 inflammation,	 thrombosis,	 and	COVID-	19	 has	 been	 es-
tablished.2	Patients	admitted	to	the	intensive	care	unit	(ICU)	have	
markedly	 elevated	 c-	reactive	 protein	 (CRP)	 levels,	 lactate	 dehy-
drogenase	 (LDH)	 levels,	 and	 d-	dimer	 levels	 among	 other	 mark-
ers.3,4 Underlying profound inflammatory states that accompany 
elevated	 biomarker	 levels	 are	 associated	with	 lung	 and	 vascular	
inflammation during infection.5	The	 severity	of	COVID-	19	 infec-
tion	is	characterized	by	extra-	pulmonary	and	extravascular	mani-
festations.5	The	cytokine	storm	identified	in	COVID-	19	infection	
is indicative of multisystem organ injuries.6 Treatments targeting 
the underlying inflammatory responses have been considered in-
cluding	 the	 steroid	dexamethasone	which	 reduces	mortality	 risk	
in	select	patients	who	require	supplemental	oxygen	or	mechanical	
ventilation.7 The inhaled budesonide has also shown efficacy in 
the	open	label	STOID	trial	in	reducing	the	need	for	urgent	medical	
care	in	patients	with	early	COVID-	19	infection.8	However,	certain	
intrinsic	 immunosuppressive	 actions	 of	 dexamethasone	 pose	 a	
challenge	 to	 its	 application	 in	COVID-	19	 patients.9 Colchicine is 
FDA-	approved	 and	 is	 one	 of	 the	 oldest	 anti-	inflammatory	 ther-
apies available with no potential immunosuppressive actions.10 
So	 far,	 it	 is	 being	 used	 for	 the	 treatment	 of	 acute	 gout,	 familial	
Mediterranean	 fever,	 and	 off-	label	 use	 for	 other	 inflammatory	
conditions.10	Mechanistically,	colchicine	inhibits	neutrophil	activ-
ity,	 an	 important	 aspect	of	 innate	 immunity.9	Further,	 colchicine	
is	observed	to	prevent	cytokine	production,	through	a	reduction	
in	 IL-	1β,	 IL-	6,	 and	 TNF	 as	well	 as	 further	 recruitment	 of	macro-
phages and neutrophils.9	 Finally,	 colchicine	 also	 acts	 to	 prevent	
the release of α-	defensin	by	neutrophils,	which	inhibits	the	inflam-
mation/thrombosis interface without directly impacting platelet 
function.9	With	 its	safe	profile,	 tolerability,	and	 low	cost,	colchi-
cine	may	be	a	useful	agent	for	COVID-	19	patients	and	has	the	po-
tential to reduce patient morbidity and mortality.
The	meta-	analysis	aims	to	determine	the	efficacy	of	colchicine	
for	patients	with	COVID-	19	compared	to	control	 (placebo	or	stan-




and	 Meta-	Analyses	 (PRISMA),	 Statement	 2020,	 clinical	 trials,	
and observational studies with a treatment group and a con-
trol group were included that reported the hematological pa-
rameters at baseline and endline. The specific outcomes were 
reported for the Colchicine treatment and Control groups. The 
meta-	analytical	 findings	 are	 pertinent	 evidence	 for	 in-	hospital	
COVID-	19	care.
2.1  |  Inclusion and exclusion criteria




groups.	 The	 studies	 comprised	 of	 adult	 participants,	 aged	 18	 or	
above,	with	any	genders.	No	follow-	up	period	was	determined	for	




2.2  |  Search strategy
A	 systematic	 search	 strategy	 was	 employed	 to	 search	 key	 elec-
tronic	 databases	 and	 clinical	 trial	 registers	 as	 per	 the	 PRISMA	
2020 Statement.11 The following databases were searched from 
December	 2019	 to	August	 26,	 2021:	MEDLINE/PubMed,	Web	 of	
Science,	Cochrane,	 Scopus,	 and	EMBASE.	Other	 sources	were	 lo-
cated	through	ClinicalTrials.	Gov,	manually	searching	SAGE,	Science	
Direct,	 Elsevier,	 and	 Google	 Scholar.	 The	 search	 terms	 across	 all	
databases	 and	 additional	 sources	 were	 as	 followed:	 Colchicine,	
covid*,	 SARS-	CoV-	2,	 anti-	inflammatory,	 trials,	 clinical,	 hematologi-
cal,	 laboratory.	There	were	no	language	restrictions.	The	titles	and	
abstracts of shortlisted studies from the databases or online sources 
were screened independently by all reviewers; in case of any disa-
greements,	 the	 final	 reviewer	was	present.	Cohen's	Coefficient	of	
Agreement	 was	 calculated	 to	 quantify	 the	 inter-	reviewer	 agree-
ments.	Figure	1	presents	the	search	process	for	the	meta-	analysis.
2.3  |  Statistical analysis
All	studies	identified	from	the	databases	were	stored	into	Endnote	
X9	 (Clarivate	 Analytics).	 The	 duplicates	 were	 removed	 using	 the	
Endnote	X9	deduplication	tool.	No	duplicates	were	found	using	the	




tion was computed.12	On	noting	 these	values,	as	 listed	 in	Table	1,	
the	standardized	mean	difference	(SMD)	was	computed,	reported	as	
Cohen's	d,	along	with	a	95%	confidence	interval	(CI).	A	fixed-	effects	
model was applied as the sample size and included study count 
was limited. Forest plots were generated for every outcome docu-
menting	 SMD,	 95%	CI,	 heterogeneity,	 and	 overall	 results	 through	
Figures	 2-	4.	 The	minimum	 requirement	 to	meta-	analyze	 the	 find-
ings was two or more studies reporting on the same outcome meas-
ure. While a funnel plot was not generated to test for publication 
bias	due	to	the	 limited	number	of	studies	(<10),	the	heterogeneity	
    |  3 of 7SARWAR et Al.




The	overall	Kappa	 score	computed	 for	 the	 inter-	reviewer	agree-
ment	was	0.86,	suggesting	good	agreement.	The	features	of	 the	
included studies with the statistical sheet are listed in Table 1. 
The	 studies	 were	 conducted	 in	 the	 USA,	 Brazil,	 Greece,	 Iran,	
and Russia. Colchicine was administered for 10– 21 days for 0.5– 
1.5 mg daily.
All	values	of	the	SMD	lesser	than	zero	indicated	the	degree	to	
which the hemodynamic lab values improved on treatment. Four 
of	the	six	studies	reported	CRP	values	in	the	Colchicine	(N	=	165)	
versus	Control	(N	=	252)	group	at	baseline	and	endline.	Negative	





Four	 of	 the	 six	 studies	 reported	 LDH	values	 in	 the	Colchicine	
(N	=	204)	and	Control	(N	=	290)	groups	at	baseline	and	endline.	On	
assessing	 whether	 Colchicine	 treatment	 reduced	 LDH	 values,	 we	







Colchicine meaning that Colchicine led to reductions in the abnor-
mally	 high	 level	 of	 fibrin	 degradation	 products	 (Cohen's	 d	=	 −0.9,	
95%	CI	=	−1.22,	−0.57,	I2 =	99%).	The	results	from	this	analysis	were	
statistically	significant	(p <	0.001).
An	 additional	 objective-	based	 summary	 of	 all	 Colchicine	 trials	
registered with ClinicalTrials. Gov is given in Table S1.
4  |  DISCUSSION
We assessed the difference in hematological parameters of pa-
tients	with	moderate-	to-	severe	COVID-	19	 infection	who	 received	
F I G U R E  1 Preferred	Reporting	Items	
for	Systematic	Reviews	and	Meta-	
Analyses	(PRISMA)	flowchart
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low-	dose	long-	term	colchicine.	Colchicine	is	one	of	the	oldest	anti-	
inflammatory	 drugs	 with	 multiple	 mechanistic	 targets.	 The	 anti-	
inflammatory	 drug,	 colchicine,	 is	 also	 highly	 effective	 in	 reducing	




nary	phase,	and	inflammatory	cascade.9 The third inflammatory cas-
cade	is	associated	with	the	activation	of	cytokines	and	chemokines	
which are targeted by colchicine.9
In	other	disease	 states	 such	as	 chronic	 rheumatic	 valvular	dis-
ease,	the	importance	of	reductions	in	serum	inflammatory	markers	
such	as	CRP	and	 IL-	6	has	been	noted	 in	a	pilot	 study.	The	 role	of	
inflammatory	markers	as	important	prognostic	and	diagnostic	tools	
have been corroborated in literature.20	 In	patients	with	moderate-	
to-	severe	COVID-	19	infection,	elevated	biomarkers	of	inflammation	
such	as	CRP	predict	the	development	of	vascular	events.	Low-	dose	
colchicine	 (0.5–	1.5	mg	 daily	 for	 10–	21	 days)	was	 observed	 to	 de-
crease	CRP	levels	in	COVID-	19	patients	in	our	study	with	a	moderate	
effect	(Cohen's	d	=	−0.49,	95%	CI	=	−0.75,	−0.23,	p <	0.001).	CRP	
is	 a	protein	 that	 is	produced	by	 the	 liver	and	 it	 is	 an	early	marker	
of	 infection	 and	 inflammation.	 Typically,	 normal	 levels	 of	CRP	 are	
less	than	10	mg/L.	However,	 it	may	rise	when	there	 is	ongoing	 in-
flammation or tissue damage within 6– 8 h.21	Additional	controlled	
studies	are	merited	to	confirm	and	assess	whether	the	use	of	long-	
term	low-	dose	colchicine	may	improve	clinical	outcomes	associated	








of	 severity	 in	mild	COVID-	19	patients	with	 a	 5%	 risk	 increase	 for	
every unit increase of CRP levels.28 The prognostic potential of CRP 
is	associated	with	inflammatory	cytokine	production	that	occurs	in	
severe	COVID-	19	 patients.	 The	 cytokine	 storm	occurs	 due	 to	 the	
hyper-	activation	of	the	immune	system	and	leads	to	tissue	destruc-
tion. The elevation of CRP levels is a predictor of higher morbidity 
and	mortality	among	COVID-	19	patients.	Consequently,	our	findings	
shed light on the protective effect of colchicine by a reduction in 
CRP	levels	among	COVID-	19	patients.
Our	 analysis	 demonstrates	 an	 association	 between	 low-	dose	
colchicine	and	a	large	reduction	in	LDH	levels	among	moderate-	to-	
severe	 COVID-	19	 patients.	 LDH	 is	 an	 intracellular	 enzyme	 that	 is	






























































































































































































































































































































































































































































































































































































































































































































































































fragment	of	 fibrin	 that	 is	 created	after	plasmin	cleaves	 it	 to	break	
down clots.33	The	d-	dimer	levels	are	indicative	of	fibrin	production	
or	breakdown.33	D-	dimer	levels	are	also	associated	with	in-	hospital	
mortality,	as	noted	by	Zhou	et	al.34 that a level of >1 μg/ml is an inde-
pendent	risk	factor	for	mortality.	Specifically,	in	COVID-	19	patients,	
elevated	d-	dimer	levels	are	indicative	of	venous	thromboembolism	









for adjuvant colchicine treatment.37
5  |  STRENGTHS AND LIMITATIONS
Our	 study	 has	 certain	 strengths	 that	may	 be	 pointed	 out.	 This	 is	
the first study that identifies a significant reduction in important 
inflammatory	 biomarkers	 for	 example,	 CRP,	D-	dimer,	 and	 LDH,	 in	
colchicine versus control groups. This study has a moderate sample 
size	with	a	significant	reduction	in	well-	known	prognostic	biomark-
ers.	While	the	individual	studies	had	small	sample	sizes,	our	pooled	
analysis is sufficient to consider colchicine for clinical practice in 
COVID-	19	infection.	A	limitation	of	this	study	was	the	lack	of	abil-
ity	to	characterize	the	severity	of	infection	on	a	case-	by-	case	basis.	
Overall,	 the	 included	sample	was	of	moderate-	to-	severe	 intensity.	
F I G U R E  2 c-	reactive	protein	(CRP)	mg/L	(mean	difference	[SD])	Colchicine	versus	Control.	SMD	=	−0.49	(95%	CI	=	−0.75,	−0.23);	
Heterogeneity: Chi² =	369.37,	df =	3	(p <	0.00001);	I²	=	99%;	Test	for	overall	effect:	Z	=	3.63	(p =	0.0003)
F I G U R E  3 Lactate	dehydrogenase	(LDH)	U/L	(mean	difference	[SD])	Colchicine	versus	Control.	SMD	=	−0.85	(95%	CI	=	−1.08,	−0.62);	
Heterogeneity: Chi² =	328.69,	df =	3	(p <	0.00001);	I²	=	99%;	Test	for	overall	effect:	Z	=	7.33	(p <	0.00001)
F I G U R E  4 D-	Dimer	ng/ml	(mean	difference	[SD])	Colchicine	versus	Control.	SMD	=	−0.9	(95%	CI	=	−1.22,	−0.57);	Heterogeneity:	
Chi² =	357.33,	df =	2	(p <	0.00001);	I²	=	99%;	Test	for	overall	effect:	Z	=	5.37	(p <	0.00001)
6 of 7  |     SARWAR et Al.




patients.8 We found that the effect of colchicine may be pronounced 
in	patients	with	ongoing	inflammatory	processes,	which	may	poten-
tially	be	observed	across	the	entire	clinical	spectrum	of	COVID-	19	
infection.	 Therefore,	 we	 recommend	 administering	 colchicine	 as	




Our	 findings	 support	 the	 use	 of	 colchicine	 in	moderate-	to-	severe	
COVID-	19	patients	with	a	rise	in	inflammatory	prognostic	biomark-
ers.	The	most	pronounced	reduction	was	observed	in	d-	dimer	levels	
followed	by	LDH	levels	and	CRP	levels	 in	our	pooled	analysis.	 It	 is	
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